Aslan Pharma of Singapore out-licensed South Korean rights for a bile-duct oncology candidate to South Korea's BioGenetics in a $13 million deal. BioGenetics will make a $2 million upfront payment and could pay up to $11 million in sales and development milestones. The two companies will collaborate to commercialize varlitinib, a small-molecule inhibitor of human epidermal growth factor, in all indications in South Korea. In H2 of 2019, Aslan expects to report topline data from a global pivotal trial of varlitinib in second-line biliary tract cancer. More details....
Stock Symbols: (NSDQ: ASLN; TPEx: 6497)
Share this with colleagues:
Original Article: Aslan Out-Licenses Korean Rights for Oncology Drug in $13 Million Deal